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Cellular activity of cyclic adenosine monophosphate 
(cAMP)-degrading phosphodiesterases (PDEs) is of 
crucial importance for the regulation of cAMP levels. 
However, PDE isoenzymes in human keratinocytes 
have not been characterized previously. In the 
present study, the PDE isoenzyme activity profile of 
the human l.:eratinocyte cell line HaCaT was investi-
gated by PDE activity measurements. In addition, the 
cAMP-mediated regulation ofPDE activities was ex-
amined. The isoenzymes PDE IV and PDE V activi-
ties were identified in HaCaT cell homogenates by 
activity measurements and were found to be prefer-
entially located in the soluble fraction. Long-term 
exposure of HaCaT cells to cAMP-elevating agents 
(e.g. , rolipram, salbutamol, forskolin) triggered a 
maximum threefold up-regulation of PDE IV activ-
ity, whereas PDE V activity was not affected. The 
c 
ycl ic nucleotides are well-known second m essen-
gers fo r the regulation of cellular respon ses . In 
keratinocytes, modulation of intracellular cyclic 
adenosine monophosphate (cA MP) m ay be in-
volved in the diffe rentiation of th ese cells [1] . An 
eleva tion of keratinocyte cAMP con centration might be attained 
either by stimulation of the cAMP-generating adenylyl cyclase or 
by inhibition of the cyclic nucleotide hydrolyzing phosphodiester-
ases (PDEs) . Human keratinocytes exhibi t a high density of {32 -
adrenergic receptors, which are fun ction aJiy co upled to the adeny-
lyl cyclase-cAMP system [2]. PDEs that degrade cAMP or cyclic 
g uanosin e m ono phosphate (cGMP) represent a multiple enzym e 
system, whi ch has been classified into seven PDE families (PDE 
l-Vll) based o n the di.fferent substrate specificities and sensitivities 
to activators and inhibitors [3,4] . Activities of PDE isoenzym es are 
subjected to a ne two rk of hormonal regulation [5]. In particular, an 
up-regula tion of rolipram-inhibited PDE TV activity , which de-
pends on de 110110 mRNA and protein synthesis, has been demon-
strated after long- term exposure to cAM.P-enha ncing agents in rat 
Sertoli cells [6] and granulosa cells [7] , myoblasts [8], chicken 
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PDE IV inhibitor rolipram synergistically amplified 
PDE IV up-regulation by /32-receptor agonists. Ex-
periments applying protein kinase A activators and 
inhibitors as well as actinomycin D and cyclohexi-
mide indicated that de rrovo mRNA and protein syn-
thesis were at least partly involved in PDE IV up-
regulation. Functio11ally, the enhanced PDE IV activity 
was reflected by an impaired cAMP response to sal-
butamol. This hyporesponsiveness toward the /32 -
adrenoceptor agonists was partly reversed by rolip-
ram. This study describes a cAMP-dependent long-
term up-regulation ofPDE IV in HaCaT cells, which 
is at least partly reflected by a simultaneous reduced 
cAMP response to a /3-agonist. Key JVords: skiu/bioclrem-
istryl/3-adreuoceptor ago11ists. J Invest Dermatol1 05:70-74, 
1995 
fibrobla sts [9] , and human monocytic U937 ce iJ s [10]. ln addition, 
short- term PDE TV up-regulation mediated by protein kinase 
A-mediated PDE IV phosphorylation may occur [11]. Enhanced 
PDE activity could indu ce a hyporesponsive cAMP m etabolism , 
and tlli s might modulate cellular fun ctions. 
PDE isoenzym e activities of human keratinocytes ha ve not yet 
been investigated. In this report, we describe PDE isoenzymes in 
the highly differentiated and immortal human kerati.nocyte cell line 
HaCaT [12]. Because sui:)stantial PDE IV activities w ere found in 
H aCaT cells , we investiga ted their regulation by cAMP-elevating 
agents and the effects of an enhanced POE lV activity on cAMP 
m etabolism in these cells. 
MATEIUALS AND METHODS 
Materials D ulbecco's modifi ed Eagle's medium, fe ta.l bovine serum, 
sodium pyruva te, and streptomycin/ pcnkillin were fi·om Gibco Life Sci-
ences B.lli (Paisley, Scotland). Substances for homogenization buffers and 
protease inhibitors, salbutmnol (a- [(t-bu tylamino)mcthyl]-4-hydroxy-m-
>:ylcnc-a,a' -diol), forskol.in (7 f3-accto>:y-la,6f3. 9a- trihydroxy-8, 13-epOA}'-
Iabd-14-en-11-onc) , dibutyryl cAMP, and cycloheximide (3-[2-(3,5-dimethyl-
2-oxocyclohexyl)-2-hydroxyethyl]glutarimide) were purchased from Sigma 
Chemic GmbH (Munk b, Germany) or Merck (Darmstadt, Germany). Fast 
protein liquid chromatography equipment, Mono Q columns, and QAE 
Sephadex A-25 were supplied by Phanmcia A.i3 (Uppsala, Sweden). 
['H]cAMP and ['H]cAMP were purchased from NEN D uPont (Wilming-
ton , DE). Quicksafe A sc intillation fluid was from Zinsser (Maid-
enhead, England). R.ol.ipram (4-(3' - cyclopcntyloxy-4' -methoxyphcnyl)-
2-pyrrolidone) , zaprinast (2-0-propO>.)'-phenyl-8-azapurine-6-one), and 
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Figure 1. Up-regulation of PDE IV activity from HaCaT cells by 
long-term incubation with rolipram and salbutamol. HaCaT ceUs 
were exposed to 10 J.LM ro lipram and 1 J.LM salbutamol (1~/S) for 6 h . After 
incubation, the cell s were washed free of drugs (three times) , removed from 
the culmre dishes, and sonicated in homogenization buffer A. PDE activities 
iJl soluble and particulate fractions (140,000 X g X 30 min) were analyzed 
at 0.5 J.LM cAMP in the presence (solid bars) and absence (opc11 bm·s) of10 J.LM 
ro lipram, as described in Materials mul M ethtJtls . Results are means from three 
to six experiments ::': SEM . 
motapizone (4.5-<iiitydro-6-[ 4-(1 H-imidazol-1-yl)-2-thienyl]-5-methyl-3(2H)-
pyridazinone) were gifts from Schering AG (l3crlin. Germany), Rhone 
Poulenc (Dagenham. England) , and Nattennann (Cologne, Germany) , 
respectively. Ro 20-'1724 [4-butoxy-(4-methoxybcnzyl)-2-imidazolidi-
none] was fi·om Hoffi11ann La R oche (Oasel. Switzerland) . Zarda verine 
[6-(difluoromctho,,y-3-methm.:yphenyi)-(2H)pyrid:. zinone], tolafentrinc 
[cis-(-)-8. 9-dimetiiOxy 2-metl1yl-6-( 4-p-toluencsulfonamidophenyl)-1.2.3 .4.4a. 
1 Ob-hexahydrobenzo[c ][1. 6]naphtyridine ]. R.P73401 [3-cyclopentylm.:y-N-
(3,5-dichloro-4-pyridyl)-4-methox")'benzamide], and tl1eophylline (1.3-di-
methybwnthine) were syntl1esized at Oyk Gulden Phanmtceuticals. Salmeterol 
( 4-hydroxy-a-[[16-( 4-phenylbutox")')hexyl J:mtino Jmethyl]-1 .3-benzenedimeth-
anol, 1-hydro>.")'-2-naphtalenecarboxylate) was from GhLxo Group R esearch. 
Calmodulin was provided by Prof. Gietzen (University ofUim. Gem1any). T he 
protein lcinase A activator Sp-5,6-DCI-cB IMPS (5 ,6-dichloro-1 ,13-D-ribo-
furanosylbenzimidazole-3' :5 '- cyclic monophosphorothioate, Sp-isomere) 
and the protein ki.nase A inhibito r Rp-8-BrcAMPS (8-bromoadenosine-3': 
5 ' - cyclic monophosphorothioate, Rp-i somcre) were supplied by Biolog 
GmbH (Bremen, Germany). Stock so lutions of drugs were generall y 
prepared in dimethylsul foxide and fu rtlt er diluted in tl1c assays . resulting in 
a fina l dimethylsulfoxide concentration of 0. 1 •y,, (v/ v). T he ['H]cAMP 
radioimmunoassay kit fo r cAMP determination was supplied by Amcrsham 
Buchl er GmbH (Braunschweig. German y). 1-laCaT cells were lcindl y pro-
vided by Pro f. N. Fusenig. German Cancer R esearch Center (Heidelberg, 
Germany). 
Culture of HaCaT Cells HaCaT ce lls were cultured to conAuency in 
Du.lbecco 's modified Eagle's medium supplemented with 10% fetal bovine 
serum , 1 mM sodium pyruvate, 50 J.Lg/ ml streptomycin. and 50 U / ml 
penicillin at 37°C in 5% C02 . 
Preparation of Subcellular Fractions HaC aT cells were removed 
from the culture dishes and homogenized in 20 mM I-IEPES. pH 7.4, 5 mM 
dithioth.re itol , 2 mM MgC12 , 5 mM ethylenediaminetetraacetic acid , 5 J.LM 
pepstatin A, 1 0 J.LM leupeptin. 50 J.LM phenylmethylsulfonyl fluoride, 1 () 
J.LM soybean trypsin inhibitor, and 2 mM benzamidine (buffer A) with a 
Branson sonifier (3 X 15 seconds; step 3-4) . The homogenate was 
centrifuged at 140,000 X g for 30 min . Supernatant and residue were 
separated, and the residue was resuspended in homogenization buffer. The 
supernatant and resuspended res idue were used as soluble and particulate 
fraction, respectively, for detennination of PDE activity . 
Chromatographic Separation of PDE I so enzymes Soluble fractions 
fro m H aCaT cells were prepared as described in the prev ious section. witlt 
the exception that cell s were sonicated in 20 mM bisTris , pH 6.5, 2 mM 
ethylencglyco l- bis(,£3-aminocthyl ether)-N.N,N' .N '-tetra acetic acid , 5 mM 
dithiotlueitol, 50 mM sodium acet,ttc, 5 J.LM pepstatin A. 10 J.LM leupeptin, 
50 J.LM phenylmcthylsulfonyl fluoride, 10 J.LM soybean trypsin inhibito r, and 
2 mM bcnzamidine (butle r 13) . Centrifuga tion was done at 140,000 X ,g for 
1 h. To separate PDE isoenzymes, supernatants were loaded onto a M ono 
Q column (bed volume 1 ml) in a fast protein liquid chromatograph y 
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systcnt. Prote ins ,,vcrc e luted \Vith a linearl y inc reasing sodiun1 acetate 
gradient (0.05 M to 1.2 M) at I ml/ min How rate. One-milliliter fractions 
were collected . and POE activi ties \VCrc n1easurcd in each frac ti o n . 
Assay of PDE Activity PDE activity was measured as described by 
T hompson and Appleman [1 3]. with modifications [14]. PDE IV activity 
was defined as the difference between cA MP-PDE activity at 0.5 J.LM cAM P 
in the presence and absence of 10 J.LM ro lipram. a selective PDE rv 
inhibi tor. 
Determination of cAMP Content in HaCaT Cells HaCaT cell s were 
incuba ted fo r 6 h with ro lipram and sa lbu tamol or vehicle. The cell s were 
thoroughly washed free of drugs and incubated for 1 0 min with 1 0 J.LM 
rolipram or vehicle . Incubations were terminated by addition of ethanol to 
a final concentration of 661X1, and cAMP \>Vas dctcnnincd by radioin1n1uno-
assay. 
RESULTS 
PDE IV and PDE V Activities Are the Main PDE Isoen-
zymes in HaCaT Cells In ceUs of the HaCaT ceU line, the 
hydrolyzing capacity of the cyclic nucleotid es cAMP and cGMP 
was more than 85'Y., r educed b y the isoenzyme-selective PDE 
inhibitors rolipram (PDE IV) and zaprinast (PDE V), respectively. 
In contrast, no influen ces on PDE activity w ere detected e ither with 
selective inhibi tors for other isoen zym es I, ll , or III or with th e 
activator of PDE I (calmodulin) or PDE II (cG MP) . T hus, human 
ke ratinocytes of th e HaCaT ceU line contain PDE IV (24 ± 2 
pmol/min/ m g protein, n = 4: m ean ± SEM) and PDE V (t 1 ± 1 
pmol/min/mg prote in , n = 4). T h e re maining activity of approx-
imately 15% was not ide ntifi e d, a lthough the insensitivity toward 
rolipram and the expression of mRNA for PDE VJI d etected by 
polym e rase chain reaction an a lysis (V. Gekeler , personal commu-
nication) sugges t the additional presen ce of PDE VJI. More than 
85% of the PDE IV and POE V activity was localized in the cytosol 
(Fig 1). 
The soluble PDE IV activity present in HaCaT ceU homoge n ates 
showe d linear e nzym e kinetics , and a typical KM value of 1.3 J.LM 
for the substrate cAMP was d e te rmin ed . In Table I , the 50% 
inhibito ry con centration values of sever al PDE inhibitors ar e sum-
marized , d e monstra ting that these dru gs inhibit cAMP-hydro lyzin g 
activity w ' th 50% inhibitory con cen tration valu es characteristic for 
PDE IV inhibition. In contrast, for m otapizon e , a PDE III selective 
inhibito r , nonspecific inhibitio n at hig h con centrations is o bserved. 
This PDE isoen zyme content was confi rmed b y Mono Q chro-
matography, where prominent peak s of PDE TV and PDE V were 
observed (data not shown). Th.is simple PDE isoen zym e profile of 
1-l aCaT cell s offers the possibility to study th e long-term regula tio n 
ofPDE IV. 
Up-Regulation of Soluble PDE IV Activities From HaCaT 
Cells Is Triggered by Long- Term Incubation With Salbu-
tamol and Rolipram Exposure of HaCaT ceUs to 1 0 J.LM 
roliprmn and 1 J.LM salbutamol, a /3~-agon.i.st, for 6 h resulted in an 
approximately tlu·eefold increase of so lu b le cAMP-PDE activity 
(Fig 1). T his activi ty increment was compl etely blocked by 1 0 J.LM 
rolipram and h e nce could be ass ig n e d to PDE fV. Kinetic analysis of 
cA MP h ydrolys is revealed tha t th e activ ity in cre ment was due to ;m 
Table I. Inhibition of Soluble cAMP PDE from HaCaT 
Cells '' 
Inhibitor Selectivity IC 50 (J.LM)1' 
Ro 20-1724 IV 0.6 :!: 0. 1 
Rolipram IV 0.2 :!: 0.04 
IUl 7340 1 IV 0.0004 ::': 0.000 1 
Zardaverine III/IV 0.25 :!: 0.04 
Tolafcntrine III/IV 0.08 ::': 0.02 
T heoph)•ll.inc I-V 204 ::': 14 
Motapizone Ill 316 :!: 12 
·• PO E activ ity w;1s measured ar 0.5 J.L-M cA MP substrate concentra tion. 
1
' 0:1t:1 a.rc cxl1rcsscd as rncan :t SEM from three l'Xpcriments. IC 50 • S0%1 inhibi tory 
·onccn tr;1 ti011. 
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approximately threefold increase in V MAX• whereas the KM re-
mained unchanged (KM = 1.3 f.LM). In the parallel clu·omato-
graphic an alysis, a threefold enlarged peak of PDE IV and an 
invariant PDE V peak were observed, confirming the selective 
increase ofPDE JV; no additional PDE activity peaks were detected 
(not shown). 
When administered alone, salbutamol up-regulated PDE IV 
activity in a dose-dependent manner (median effective concentra-
tion 16 nM) to a maxin1al twofold increase, whereas 10 fLM 
rolipram alone did not affect PDE IV activity. The co-incubation of 
both, however, synergistically elevated PDE IV activity threefold 
(Fig 2). T he median effective concentration was decreased in the 
presence of rolipram from 16 nM to 1.6 nM. Neither the PDE 
activity in the particulate fraction (Fig 1) nor PDE V activity was 
affected by incubation of HaCaT cells with the combination of 
rolipram and salbutamol. 
Incubation ofHaCaT Cells With Salbutamol and Rolipram 
and Their Withdrawal Result in a Time-Dependent PDE IV 
Activity Up-Regulation and Decay Exposure ofHaCaT cells 
to 10 fLM rolipram and 1 fLM salbutamol revealed a continuous 
augmentation in PDE IV activity, which was signiftcant after 30 
min and reached a plateau after 6-12 b (Fig 3). Withdrawal of 
rolipram and salbutamol after 6 h of incubation led to a fast decrease 
i.n PDE IV activity. T he decay followed first-order kinetics, and a 
half-time of 66 min was calculated (Fig 4). 
Activation of Protein Kinase A as Well as de 110110 mRNA 
and Protein Synthesis Are Involved in Up-Regulation of 
PDE IV Activity A two- to threefold e levation of soluble PDE 
IV activity was also obtained after 6 b of exposure of HaCaT cells 
to the adenylyl cyclase stim ulant forskolin (100 fLM), dibu tyryl 
cAMP (500 f.LM), or the specific protein kinase A activator Sp-5,6-
DCl-cBIMPS (Fig 5). However, incubation with rolipram and 
sal.butamol in the simultaneous presence of the protein kinase A 
inhibitor Rp-8-Br-cAMPS (500 f.LM) partially reversed (35%) the 
PDE IV up-regulation. Actinomycin D (2.5 f.Lg/ml), an mRNA 
synthesis inhibitor, and cycloheximide (25 fLM), a protein synthesis 
inhibitor, significantly attenuated the PDE TV up-regulation trig-
gered by rolipram and salbutamol by approximately 56% and 57%, 
respectively. Higher concentrations of actinomycin D or cyclohex-
imide did not further inhibit the up-regulation of PDE IV. 
PDE IV Up-Regulation in HaCaT Cells Results in a Re-
duced cAMP Response to /3-Agonists, Which Is Partly 
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Figure 2. Salbutamol in the presence of rolipram up-regulates 
soluble PDE IV activity in a concentration-dependent manner. 
HaCaT ce lls were incubated for 6 h with different concentrations of 
salbu tamol in the presence (closed sy•niJO is) and absence (open symbols) of 10 
f.LM rolipram. After the end of the incubation period, soluble fractions were 
prepared as explained in Fig 1 and Mnterinls mod Metllods . POE IV activities 
were determined as the difference between cAMP-hydro lyzing activities 
(0.5 j.~.M cAMP) in the presence and absence of 1 0 j.~.M rolipram. R.esnlts are 
means from three experiments ::':: SEM. Ctr, control. 
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Figure 3. PDE IV up-regulation by rolipram and salbutamol is 
time dependent. HaCaT cells were exposed for different times (15 min to 
24 h) to 1 f.LM saJbutamol and 10 j.~.M rolipram. Soluble fractions were 
prepared as described in Fig 1 and Mnterinls n~~d Methods. PDE IV activities 
at 0.5 j.~.M cAMP were determined at each time point in soluble fractions. 
Results arc from two e"-periments perfonncd in duplicate. *p < 0.05 
compared with control (ctr) activity. 
Reversed by PDE IV Inhibitors As shown in Table II, a 
highly significant, concentration-dependent increase in cellular 
cAMP content was observed after incubation of cells for 5 min with 
salbutamol. Furthermore, this cAMP increase was synergistically 
enhanced by preincubation with 10 fLM rolipram for 10 min (Table 
II), which, when given alone, only modestly increased cAMP 
concentrations from 3.5 :±: 0.2 pmollmg protein (basal) to 11.4 ::':: 
0.5 pmol/mg protein (10 fLM rolipram, n = 3; mean :±: SEM). 
However, in cells pretreated by rolipram and salbutamol for 6 h , no 
significant cAMP increase was seen after incubation with 1 fLM 
salbutamol for 5 min. Furthermore, under these conditions, prein-
cubation with 10 fLM rolipram could only partially restore the 
blunted cAMP response to salbutamol (Table II). 
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Figure 4. Withdrawal of salbutamol and rolipram results in a 
time-dependent reversal of the PDE IV up-regulation. HaCaT cells 
were incubated with 1 f.LM salbutamol and 10 f.LM rolipram for 6 h. To 
remove drugs after tllis incubation period, the cells were washed three times 
with medhun, and incubations were continued for the times indicated. 
Soluble fractions were prepared as described in Fig 1 and Materials a"d 
Metloods. Soluble PDE IV activity at 0.5 !-lM cAMP was measured at the 
indicated times, and the data were fitted according to first-order kinetics. 
Results are from two experiments performed in duplicate. 
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Figure 5. Evidence for a role of protein kinase A (PKA) activation 
and de rr o11o mRNA and protein synthesis in PDE IV activity 
up-regulation. HaCaT ce ll s were incuba ted with either 10 !J.M rolipram 
+ 1 !J.M sa lbucam o l, 100 !J.M forskolin, 500 !J.M dibutyryl cAMP (db-
cAMP), o r 500 !J.M Sp-5.6-DCl-cBIMPS (protein kinase A activator) fo r 6 
h . ln som e experiments, cell s were pretrea ted with either 500 !J.M Rp-8-
Br-cAMPS, 2.5 J.Lg/ml actinomycin D. or 25 !J.M cycloheximide for 1 h 
before lO !J.M ro lipram and 1 !J.M salbutamol was added, and the incubation 
was con thlll ed for another 6 h . After the incubatio n period, soluble fractions 
were prepared as described in Fig 1 and Materials flllrl Methods. Soluble POE 
IV activity was determined at 0.5 !J.M cA MP. Results arc m eans fro m d1ree 
to six experiments ± SEM. *Signifi cantly greater than control values, p < 
0 .01; ** significandy less than values with rolipram and salbutamol alone: p 
< 0.05 , protci.n kinase A inhibitor; p < 0.01, cycloheximide and actinomy-
cin D . 
DISCUSSION 
PDE IV represents the major cAMP-hydrolyzing activity in HaCaT 
cells, and is found also h1 inflammatory cells such as neutroph.ils, 
eosinophils, T lymphocytes, monocytes, and alveolar macrophages 
(15] and was demonstrated as a prominent PDE activity in primary 
cultured human keratinocytes (16]. T herefore, HaCaT cells could 
serve as a relev<mt model for PDE IV activity regulation in human 
keratinocytes. This study focused on the long-term regulation of 
PDE IV activity by cAMP-elevating agents and its impact on 
cellular cAMP metabolism in H aCaT cells. We found significant 
up-regulation of PDE IV activity after trea tment of HaCaT cells 
with rolipram and salbutamol for 6 h. Three lines of eviden ce 
indicate that this up-regulation is m ediated, at least in part, by 
protein kinase A activation: 1) the PDE IV inhibitor rolipram 
synergistically amplified the effect of salbutamol on PDE IV up-
regulation; 2) PDE IV was up-regulated after incubation with a 
specific protein kinase A ac tivator; and 3) a protein kinase A 
inhibitor significantly inhibited the up-regulation of PDE IV activ-
ity induced by rolipram and salbutamol. T he relatively modest 
effect of the protein kinase A inhibitor might be due to limited 
penetration of the compound into th e cells, although we cam1ot 
exclude tl1at mechanisms other than protein kinase A activation 
partly account for the PDE IV up-regulation . ln other cellular 
systems, the pivotal role of protein kinase A activation in cAMP-
Table II. Effect of Enhanced PDE IV Activity on 
Agonist-Mediated cAMP Response in HaCaT Cells" 
Basal 
O.l!J.M S 
IJ.LMS 
0.1 !J.M S + 10 !J.M R 
1 !J.M S + 1 0 !J.M R. 
cAMP (pmol/ m g protein) 
Control 
3.5 ± 0.2 
59.2 ± 3.3 
774 ::': 36 
74 1 ::': 87 
2260 ± 131 
R/S Exposedt. 
29.8 ::': 2.4 
34.8 ::': 4.4 
37.5 ::': 3 .3 
189 ::': 15 
487 ± 53 
11 Data arc expressed as mean ~ SEM from three experiments. R.., roUpr~m; S. 
salbu tamol. 
b C c Us were exposed for 6 h to 10 J..LM rol.ipram plus 1 ,u.M salbutam o l. 
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mediated PDE IV up-regulation was recently demonstrated by 
different tools using protein kinase A mutant-transfected myobla.sts 
[17] and protein kinase A-deficient mouse lymphoma cells [18] . 
The reversal of PDE IV up- regulation by simultaneous incuba-
tion with cyclohexi..nlide or actinomycin D indicates the parti.cipa-
tion of de novo mRNA and protein synthesis in tlus process. 
Preliminary experiments have indicated that the effects of cyclo-
heximide and actinomycin D are not due to interference with 
intracellular cAMP concentrations, as we found no effect of both 
agents on basal or salbutamol-stimulated cAMP concentrations. 
Tllis observation is confirmed by recent investigations in U93 7 cells 
[10]. Taking into account the incomplete inhibition of PDE IV 
up-regulation by actinomycin D and cycloheximide, and in view of 
the significant increase of PDE IV activity after 30 min of incuba-
tion with salbutan10l and rolipram, short-tenn PDE IV up-regula-
tion independent of de 11ovo protein synthesis cannot be excluded 
from contributing in part to PDE IV up- regulation. R ecently, 
cAMP-mediated phosphorylation and simultaneous increase in 
activity ofPDE IV was demonstrated in FRTL-5 cells [11]. 
Different PDE IV subtypes have been described recently [1 9]. 
However, from this study it remains an open question whether the 
appearance of different PDE IV subtypes might account for the PDE 
IV up-regulation . 
The functional consequence ofPDE IV up-regulation in HaCaT 
cells is reflected by an impaired cAMP increase in response to 
salbutamol, which could be partially restored by rolipram (Table 
II). Tllis may indicate that /3-agon.ist-mediated PDE IV up-regula-
tion triggers toleran ce toward the actions of /3-agmlists, wlli.ch can 
be reversed by PDE inhibitors . Because ro lipram could not com-
pletely restore the impaired cAMP increase (Table II), it must be 
assumed that other mechanisms, such as /3-arres tin-mediated [20] 
and /3-adrenoceptor kinase-mediated [21] m odulation of the /3-re-
ceptor complex, might be involved in the hyporesponsiveness of 
the cAMP-generating system. An impaired cAMP response to 
hormonal agmlists, which was paralleled by an up-regulated PDE 
IV activity, was described recently in rat Sertoli cells; fi.mctionally, 
impaired honnone-i..nduced androgen aromatization was demon-
strated as a consequence of PDE IV up-regulation [22]. In this 
cellular system , the addition of a PDE inllibitor could restore the 
original cAMP production and androgen aromatization. 
PDE IV and PDE V isoenzyme activities were identified in 
HaCaT cell homogenates. Soluble PDE IV activity was up-regu-
lated after long- tem1 exposure ofHaCaT cells to salbutamol alone 
or i11 combination with rolipram. We demonstrated that protein 
kinase A activation and de IlOilO mRNA and protein synthesis are 
involved in m ediating tllis up-regulation ofPDE IV activity. It was 
further shown that the up-regulated PDE activity caused significant 
changes in cellular cAMP metabolism and concentrations. 
REFERENCES 
1. Green 1-l : Cyclic AMP in re lation to proliferation of the epiderma l cc.IJ : a n ew 
view. Ce/11 5:801 - 81 1. 1978 
2. Steinkraus V, Stein Htth M. KOrner C , Mensing H: Binding of beta-adrenergic 
receptors in human skin. J ilwcsr D cm wtol 98:4 75- 480, 1992 
3. Bcavo JA, R eif.'inydcr DH: Primary sequence of cyclic nucleotide phosphodies-
terase isozyn1es and the design of selective inhibitOrs. Tremls Pltamwcol Sci 
11 :150-155, 1990 
4. MichaeU T. Bloom TJ , Martins T , Loughney K, Ferguson K Riggs M, Rodgers 
L, Bcavo J A, Wiglcr M: Isolation and characterization of a previously 
undetected human cAMP phosphodiesterase defi cient Saccharomyces ccrcvi-
siac. J Bioi C/lem 268: 12925-12932 , 1993 
5. Conti M , Jin SLC, Monaco L, Rcpaske DR. Swinnen JV: H onnonal regulation 
of cyclic nucl eotide phosphodiesterases. Erulocr Rcr' 12:218-233. 1991 
6. Conti M. Geremia R , Adam o S, Stc t3nini M: Regulation of Scrtoli cell cyclic 
adenosinl! 3 ' :5 ' nJOnophospltate phosphodiesterase acthrity by fu ll.icle stinlu-
lating hormone and dibutyryl cAMP. Bioc/rcm Bioplr)'s Res Co.rrrrrrrrrr 98:1044-
1050. 1981 
7. Conti M , K01son BG, Hsuch AJW: Honnonal regulation of 3' :5 ' -adcnosiuc 
monophosphate phosphodiesterase in cultured rat granulosa cells . .E11docriuology 
114:2361-2368. 1984 
8. Ball EH , Seth PK, Sanwa1 BD: Regulatory mechanisms involved in r.hc control of 
cyclic adenosine 3':5 '-monophosphatc phosphodiesterase in Jnyoblas ts.j Bioi 
C lr cm 2 55:2962-2968, 1980. 
74 TENOR. rn · AL 
9. Russel TR. Pastan IH : Cyclic adenosine 3 ':5'-monophosphate and cyclic 
guanosine 3' :5' -monophosphatc phosphodiesterase activities arc under sepa-
rate genetic control.) Bioi C /wm 249:764-7769, 1974 
10. Torphy TJ, Zhou HL, Cieslinski L: Stimulation of beta adrenoceptors in a human 
mo nocytic cell H11e (U 937) up-regula tes cyclic AMP-specifi c phosphodiester-
ase activiry. J 1'/wrmnco/ Exp Tl~er 263:1195-1205, 1992 
t t. Sette C. lana S, Conti M: The short term activation of a roliprarn-sensitivc, 
cAMP-specif•c phosphodiesterase by thyroid-stimulating honnonc in thyroid 
F l~TL-5 cells is mediated by a cAMP-dependent phosphorylation.) Bioi C lwm 
269:9245-9252 , 1994 
12. Boukamp P, Petrussevska RT, Breitkreutz D. Honmg J, Markham A, Fuscnig 
NE: Normal kcratini zottion in a spontaneously inunortalizcd aneuploid human 
keratinocyte cell line.) Cell Bio/106:761-771, 1988 
13. T hompson WJ, Appleman MM: Assay of cyclic nucleotide phosphodiesterase 
and reso lu tion of multiple molecular forms of the enzyme. At/11 C ycl Nuc/ Res 
I 0:69-92, 1979 
14. Bauer AC, Schwabe U: An improved assay of cyclic 3' :5'-nucleotide phospho-
diesterase with QA.E Scphadcx A-25. Na"">'" SclmriedciJerss Arch Plranuac(l[ 
311:193-198 , 1980 
·1s . Torphy T]. Undem BJ: Phosphodiesterase inhibitors: new opportunities for the 
treatment of asthma. T horax 46:512-523, 1991 
THE J OURNAL OF INVESTIGATIVE DEL~ATOLOGY 
16 . Wright S, Navsaria H, Leigh IM: Cyclic adenosine monophosphate-phospho-
diesterasc activity in cultured kcratinocytes from patients w ith atopic eczema. 
J D cmwtol Sci 2:263- 267, 1991 
17. Kovala T , Lorimer IAJ, Brickcndcn AM . Ball EH, Sanwal B: Protein kinase A 
regulation of cAMP phosphodiesterase e'-l'rcssion in rat skele tal myoblasts. j 
Bioi C hcm 269:8680 - 8685, 1994 
18. Bou.rnc HR, Tomkins GM, Dion S: Regulatio n of phosphodiesterase synthesis: 
requirement for cyclic adenosine monophosphate-dcpcndent protein kinase. 
Scieuce 181 :952-954, 1973 
19. Obernoltc R, llhakta S, Alvarez R , Bach C, Zuppan P, Mulkins M, Jarnagin K, 
Shelton ER: The eDNA of a human lymphocyte cyclic AMP phosphodiester-
ase (POE IV) reveals a multigcnc family. Gene 129:239-247, 1993 
20. Parruti G, Pcracchia F, Sallcsc M, Ambrosini G, Masini M, Rotilio 0, DcB iasi A: 
Molecular analysis of hun1;_m /3-arrestin-1: cloning, tissue distribution, and 
regulatio n of expression. J Bioi Chcm 268:9753-9761 , 1993 
2 1. Lohse MJ , Andexingcr S, Pitcher J, Trukanowski S, Codina J , Faure JP, Caron 
MG. Lefkowitz RJ: Receptor-specific desensitization with purified proteim. j 
Bioi C hcm 267:8858- 8564 , 1992 
22. Conti M, Monaco L, Gcrernia R . Stcfanlni M: Effect of phospho diesterase 
inhibitors on Sertoli cell re&:1ctorincss : reversal of the impaired androgen 
aromadzation . E11docriuology 11 8:901-908, 1986 
